Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.


OTCPK:HALB - Post by User

Halberd Corp > Halbert corp. - greatest phantasy is not enough.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Post by badgirl007on Jul 20, 2021 2:12pm
246 Views
Post# 33576022

Halbert corp. - greatest phantasy is not enough.

Halbert corp. - greatest phantasy is not enough.
Still undiscovered and simply not to be believed:
 
Whenever a company manages to develop an exclusive treatment method that no other pharmaceutical company is allowed to replicate,
 
then profits of several thousand, even several tens of thousands of percent are possible.
 
What do you think all investors would get out of a successful treatment for Alzheimer's disease?
 
And that would be just the beginning of the diseases that can be combated with their methods.

Do your own research.

https://halberdcorporation.com/news/

Currently still almost a gift!
https://www.otcmarkets.com/stock/HALB/profile

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities